Green Cross LabCell Applies for Phase 1 Clinical Trial of Stem Cell Therapy for Psoriasis Patients
[Asia Economy Reporter Ji Yeon-jin] Green Cross LabCell announced on the 21st that it has applied for a Phase 1 clinical trial to evaluate the safety, tolerability, and efficacy of single and repeated doses of allogeneic tonsil-derived mesenchymal stem cells (CT303) in patients with severe plaque psoriasis.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Over 7,000 Residents Evacuate Urgently" Magnitude 5.2 Earthquake Leaves 2 Dead, 6 Injured... What Happened in China?
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
